Servier, a global pharmaceutical group governed by a foundation, has reinforced its India strategy with the launch of GATINN — a dedicated platform for the development, manufacturing and export of Single Pill Combinations (SPCs) targeting cardiometabolic and venous diseases. The initiative is designed to simplify complex treatment regimens, enhance patient adherence and improve long-term health outcomes. It also aligns with the company’s broader Servier 2030 vision of accelerating innovation and delivering more patient-centric therapies for chronic illnesses.
Single Pill Combinations bring multiple medicines together in a single tablet, reducing pill burden and enabling patients to follow prescribed treatments more consistently. By prioritising SPC development, Servier seeks to address one of the most persistent challenges in chronic disease management — poor adherence — ultimately supporting better clinical outcomes and stronger disease control globally.
To drive the platform’s growth, Servier plans to invest around €15 million in 2026 and will work closely with Indian partners to scale up manufacturing and ensure timely delivery.
Also Read